Registration
 
All news
Top Stories
Editors' Picks
Stocks
Crypto
Economics
Currencies
Commodities
Business & Wealth
Market Voices
Oleg Tkachenko
Oleg Tkachenko

Ocugen appoints Beth Scott as VP to lead clinical development strategy

Ocugen appoints Beth Scott as VP to lead clinical development strategy
Ocugen hires VP for clinical trials

Ocugen has appointed Beth Scott as Vice President and Head of Clinical Development, leveraging her three decades of ophthalmology expertise.

Scott will lead efforts in retinal clinical development and trial execution as Ocugen progresses pipeline candidates OCU400, OCU410, and OCU410ST. The company aims to strengthen its clinical leadership as it moves forward with these key gene therapy programs.

Ocugen has previously investigated RORα as a multi-pathway target in Alzheimer research, focusing on neuroinflammation and mitochondrial health, according to a recent article. The company has also spotlighted the impact of geographic atrophy on vision and eye health in the retina, as noted in another report. These initiatives reflect an ongoing commitment to advancing therapies in retinal diseases.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Editor's Picks for You

Ryanair tightens its belt: How rising fuel prices threaten the budget airline
  • By Eugene Komchuk
  • 1 hour ago
Ryanair tightens its belt: How rising fuel prices threaten the budget airline
Editors' Picks
How German metalworkers’ strikes are testing Europe’s industrial strength
  • By Dmytro Kharkov
  • 3 hours ago
How German metalworkers’ strikes are testing Europe’s industrial strength
Editors' Picks
DeFi for the select few: Why Hyperliquid is building restricted markets
  • By Pavlo Kot
  • Yesterday
DeFi for the select few: Why Hyperliquid is building restricted markets
Editors' Picks
All Editors' Top Picks

Latest Ocugen News

Ocugen introduces master regulator gene approach in novel blindness treatment initiative
  • By Pavlo Kot
  • 27.10.2026
Ocugen introduces master regulator gene approach in novel blindness treatment initiative
Companies
#Ocugen
Ocugen to present 3Q 2026 financial results on November 4
  • By Elena Nikulina
  • 22.10.2026
Ocugen to present 3Q 2026 financial results on November 4
Companies
#Ocugen
Ocugen moves OCU410 gene therapy for geographic atrophy into Phase 3 trial
  • By Alena Volkova
  • 20.10.2026
Ocugen moves OCU410 gene therapy for geographic atrophy into Phase 3 trial
Companies
#Ocugen
All Ocugen News
  • Eugene Komchuk
  • 1 hour ago
Ryanair tightens its belt: How rising fuel prices threaten the budget airline
  • Dmytro Kharkov
  • 3 hours ago
How German metalworkers’ strikes are testing Europe’s industrial strength
  • Pavlo Kot
  • Yesterday
DeFi for the select few: Why Hyperliquid is building restricted markets
  • Pavlo Kot
  • 31.10.2026
Can Bitcoin make you a millionaire?
  • Olena Litvinenko
  • 30.10.2026
France's crypto market matures as regulation reshapes the industry
  • Eugene Komchuk
  • 7 min ago
India has exceptional Web3 developer talent, Sumit Gupta notes
  • Igor Krasulya
  • 22 min ago
Kate Miller: $INKKY shows $10.4 million market cap and $5.5 million liquidity on Solana
  • Mykhailo Ihnatenko
  • 27 min ago
Structured notes market attracts wealthy clients with $300 billion size, Alex Micalizzi states
  • Pavlo Kot
  • 34 min ago
Quinten Francois: Market response to major exchange hack is notable
  • Hanna Syniavska
  • 35 min ago
Brian Armstrong: Coinbase adds 18,000th Bitcoin to treasury investment holdings
Top News
  • Igor Krasulya
  • 50 min ago
Alphabet returns to euro bond market despite disappointing earnings
Alphabet returns to euro bond market despite disappointing earnings
  • Ivan Andriyenko
  • 1 hour ago
Gold climbs above $3,900 as bargain hunters return after October rout
Gold climbs above $3,900 as bargain hunters return after October rout
  • Andrey Mastykin
  • 2 hours ago
Anthropic taps Japanese investors ahead of major U.S. listing as AI financing expands
Anthropic taps Japanese investors ahead of major U.S. listing as AI financing expands
  • Olga Shendetskaya
  • 3 hours ago
Gulf states urge Washington to avoid new confrontation with Iran
Gulf states urge Washington to avoid new confrontation with Iran
  • Eugene Komchuk
  • 4 hours ago
Binance customers withdraw $5.8 billion in wake of hack
Binance customers withdraw $5.8 billion in wake of hack
Live News
  • Anton Kharitonov
  • Now
EUR/USD struggles to sustain recovery as eurozone risks persist
  • Eugene Komchuk
  • Now
Hong Kong launches 24/7 settlement for tokenized assets
  • Mykhailo Ihnatenko
  • Now
Ethereum price struggles above $2,300 despite $63M whale purchase
  • Andrey Mastykin
  • Now
Eurozone economy slows as France slips into recession fears
  • Anton Kharitonov
  • Now
EUR/USD recovery stalls near 1.1210 as dollar retains its fundamental advantage
Who We Are
Business Solutions
For Users
TU News
Popular Sections
Disclosures
CONTACT US
Legal
We are in Social Media
© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186
  • Risk disclosure:

    Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

    That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.

  • Disclaimer:

    Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

    Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.

  • Disclosure of advertisers and revenues:

    All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

    Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.

onepercentfortheplanet.org https://gdpr.eu/ GDPR World Association of News Publishers